Department of Global Health, Academic Medical Center, University of Amsterdam, Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands.
Expert Rev Anti Infect Ther. 2014 Jan;12(1):5-7. doi: 10.1586/14787210.2014.859984.
Infection with HIV is one of the strongest drivers of the incidence of tuberculosis. The use of potent combination antiretroviral therapy (cART) decreases the incidence of tuberculosis in HIV-infected patients. Data on whether this effect differs by type of initial antiretroviral drug or regimen are scarce. Studies are often not designed to address the potential effect of cART on tuberculosis incidence, and/or the diagnosis of tuberculosis is poorly validated. The paucity of data precludes recommendation on the initial cART regimen with respect to the incidence tuberculosis. Other well-described intervention like preventive therapy, and early start with cART are likely to have more effect on the prevention on tuberculosis in HIV-infected patients.
感染 HIV 是导致结核病发病率的最强驱动因素之一。使用强效的联合抗逆转录病毒疗法（cART）可降低 HIV 感染者中结核病的发病率。但是关于初始抗逆转录病毒药物或方案类型是否会对此产生影响的数据却很少。这些研究通常不是为了确定 cART 对结核病发病率的潜在影响，并且/或者结核病的诊断也未得到很好的验证。数据的缺乏使得我们无法针对 cART 方案的初始治疗来推荐降低结核病发病率的方案。预防性治疗等其他经过充分描述的干预措施以及尽早开始 cART 治疗可能对预防 HIV 感染者中的结核病更有效。
